 Adamis Pharmaceuticals finished 2020 with some Malheur with the company receiving its second CRL for ZIMHI. However, the company is a making a strong comeback thus far in 2021. Adamis plans to appeal the FDA decision on ZIMHI and has requested a Type A meeting. If all goes well, we could see ZIMHI approved in the coming months. 